Clinical Trials
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
Lead Researcher: Brea C Lipe
This trial will study SEA-BCMA, a monoclonal antibody, to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SEA-BCMA should be given for treatment and how often. Part 2 of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.
View Study Details
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Lead Researcher: Brea C Lipe
Patients will be treated with Daratumumab and Lenalidomide or Lenalidomide alone for two years and then tested for minimal residual disease. Minimal residual disease is the evidence for the presence of residual malignant cells, even when so few cancer cells are present that they cannot be found by routine means. In a patient who has been treated, the detection of MRD indicates that treatment is incomplete. MRD can thus distinguish who needs intensive and potentially more toxic therapy from those who do not. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be either continue or discontinue the assigned treatment. Patients are treated for up to 7 years and followed for up to 15 years.
View Study Details
IMMY17015: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies
Lead Researcher: Brea C Lipe
This research is being done to help us determine if the study drug is safe and can be tolerated for the treatment of multiple myeloma or certain lymphomas.
View Study Details
ULAB-16115 A program for following disease progression in Multiple Myeloma
Lead Researcher: Brea C Lipe
The purpose of this study is to collect clinical data along with bone marrow aspirate samples to see if there is a way to determine which patients are more or less likely to experience disease progression. This study will involve identifying different markers on the surfaces of the plasma cells and will look at protein expression. We will then correlate those findings with data from your medical records over time.
If you decide to take part in this study, you will be asked to allow additional bone marrow aspirate and blood samples to be collected for research at several time points. These additional samples will be collected during routine testing time points as required for your routine care. We will also collect information about your disease and treatment from your medical record.
View Study Details
IMMY-16088 A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma),IMMY-16088 A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma)
Lead Researcher: Brea C Lipe
This is an open-label study, which means that both you and your study doctor will know how much selinexor and the names of other medications you are taking. You, and all other patients in this study, will take the study drug selinexor, plus dexamethasone and either pomalidomide, bortezomib, lenalidomide, or daratumumab. The treatment period consists of blocks of time called cycles. The number of treatment cycles you receive will depend on how well you are doing on the treatment and how well your cancer responds to it.
This study includes four different treatment combinations:
• Selinexor, dexamethasone and pomalidomide (abbreviated as SPd)
• Selinexor, dexamethasone and bortezomib (abbreviated as SVd)
• Selinexor, dexamethasone and lenalidomide (abbreviated as SRd)
• Selinexor, dexamethasone, daratumumab (abbreviated SDd)
View Study Details
UMMY17073: A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency
Lead Researcher: Brea C Lipe
If you decide to participate in this study you will receive denosumab every 4 weeks for a total of 12 cycles.
View Study Details
A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Lead Researcher: Brea C Lipe
This research study is studying a combination of study drugs as a possible treatment for
relapsed and refractory Multiple Myeloma. The interventions involved in this study are
elotuzumab, pomalidomide, bortezomib, dexamethasone.
View Study Details
Publications
Journal Articles
4/9/2019
Li D, Chiu G, Lipe B, Hopkins RA, Lillis J, Ashton JM, Paul S, Aljitawi OS. "Decellularized Wharton jelly matrix: a biomimetic scaffold for ex vivo hematopoietic stem cell culture." Blood advances.. 2019 Apr 9; 3(7):1011-1026.
4/1/2019
Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin T. "Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2019 Apr 1; :JCO1802096. Epub 2019 Apr 01.
1/2019
Hsu CM, Bennett JM, Lipe B. "Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma." Clinical lymphoma, myeloma & leukemia.. 2019 Jan 0; 19(1):e29-e32. Epub 2018 Sep 05.
VIEW ALL PUBLICATIONS